$SSY
SUNLINK HEALTH SYSTEMS INC Stock $ssy

$ssy Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-K Financial Statement

#000095017023050285 Filed on September 28, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2023
Revenue	$8.555M	$10.99M	$47.95M
YoY Change	-22.49%	11.19%	15.98%
Cost Of Revenue	$4.771M	$4.929M	$18.60M
YoY Change	9.2%	16.03%	13.3%
Gross Profit	$3.784M	$6.058M	$29.40M
YoY Change	-43.25%	7.54%	17.94%
Gross Profit Margin	44.23%	55.14%	61.32%
Selling, General & Admin	$3.028M	$6.192M	$25.20M
YoY Change	-55.6%	-0.91%	3.36%
% of Gross Profit	80.02%	102.21%	85.71%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$300.0K	$596.0K	$1.765M
YoY Change	-18.48%	29.57%	14.39%
% of Gross Profit	7.93%	9.84%	6.0%
Operating Expenses	$4.234M	$8.033M	$31.70M
YoY Change	-48.87%	2.41%	4.73%
Operating Profit	-$450.0K	-$1.975M	-$2.322M
YoY Change	-72.1%	-10.67%	-56.52%
Interest Expense	$22.00K	$74.00K	$100.0K
YoY Change	-650.0%	2366.67%	-766.67%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$426.0K	-$1.436M	-$1.662M
YoY Change	-72.41%	-35.02%	2.91%
Income Tax	$2.000K	$0.00	-$7.000K
% Of Pretax Income
Net Earnings	-$1.344M	-$1.426M	-$1.795M
YoY Change	-13.74%	-39.7%	-10.65%
Net Earnings / Revenue	-15.71%	-12.98%	-3.74%
Basic Earnings Per Share	-$0.19		-$0.26
Diluted Earnings Per Share	-$0.13	-$0.20	-$0.26
COMMON SHARES
Basic Shares Outstanding	7.032M	7.032M	7.019M
Diluted Shares Outstanding	7.033M		7.019M

Balance Sheet

Concept	2023 Q3	2023 Q2	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.820M	$4.486M	$4.500M
YoY Change	-43.04%
Cash & Equivalents	$2.820M	$4.486M	$4.500M
Short-Term Investments
Other Short-Term Assets	$9.345M	$1.783M	$1.800M
YoY Change	331.44%
Inventory	$1.602M	$1.754M	$1.800M
Prepaid Expenses
Receivables	$2.764M	$4.251M	$4.300M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$16.53M	$12.27M	$12.30M
YoY Change	7.3%	-27.01%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.891M	$8.281M	$9.300M
YoY Change	-65.92%	0.78%
Goodwill
YoY Change
Intangibles	$1.180M	$1.180M
YoY Change	-1.26%	-1.75%
Long-Term Investments
YoY Change
Other Assets	$389.0K	$489.0K	$500.0K
YoY Change	-38.25%	-6.5%
Total Long-Term Assets	$5.192M	$11.00M	$11.00M
YoY Change	-54.54%	-1.2%
TOTAL ASSETS
Total Short-Term Assets	$16.53M	$12.27M	$12.30M
Total Long-Term Assets	$5.192M	$11.00M	$11.00M
Total Assets	$21.72M	$23.27M	$23.30M
YoY Change	-19.02%	-16.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.359M	$1.849M	$1.800M
YoY Change	-25.78%	37.27%
Accrued Expenses	$2.179M	$2.986M	$3.000M
YoY Change	-62.57%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$3.000K	$14.00K	$0.00
YoY Change	-92.68%	-65.0%
Total Short-Term Liabilities	$4.993M	$4.869M	$4.900M
YoY Change	-38.83%	-36.69%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Other Long-Term Liabilities	$113.0K	$102.0K	$900.0K
YoY Change	-0.88%	-3.77%
Total Long-Term Liabilities	$651.0K	$983.0K	$900.0K
YoY Change	-38.18%	-13.16%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.993M	$4.869M	$4.900M
Total Long-Term Liabilities	$651.0K	$983.0K	$900.0K
Total Liabilities	$5.644M	$5.852M	$5.900M
YoY Change	-38.76%	-33.67%
SHAREHOLDERS EQUITY
Retained Earnings	$1.661M	$3.005M
YoY Change	-48.77%	-37.4%
Common Stock	$14.27M	$14.26M
YoY Change	0.04%	0.34%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$16.08M	$17.42M	$17.40M
YoY Change
Total Liabilities & Shareholders Equity	$21.72M	$23.27M	$23.30M
YoY Change	-19.02%	-16.73%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2023
OPERATING ACTIVITIES
Net Income	-$1.344M	-$1.426M	-$1.795M
YoY Change	-13.74%	-39.7%	-10.65%
Depreciation, Depletion And Amortization	$300.0K	$596.0K	$1.765M
YoY Change	-18.48%	29.57%	14.39%
Cash From Operating Activities	-$1.137M	-$421.0K	-$540.0K
YoY Change	-10.54%		13400.0%
INVESTING ACTIVITIES
Capital Expenditures	$476.0K	$475.0K	$2.000M
YoY Change	-23.72%		-37.3%
Acquisitions
YoY Change
Other Investing Activities	$5.000K	$11.00K	$220.0K
YoY Change	-90.2%		2100.0%
Cash From Investing Activities	-$524.0K	-$464.0K	-$1.776M
YoY Change	-6.76%		-43.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net	$11.00K		$40.00K
YoY Change	10.0%		11.11%
Cash From Financing Activities	-5.000K	-11.00K	8.000K
YoY Change	-50.0%		-122.22%
NET CHANGE
Cash From Operating Activities	-1.137M	-421.0K	-540.0K
Cash From Investing Activities	-524.0K	-464.0K	-1.776M
Cash From Financing Activities	-5.000K	-11.00K	8.000K
Net Change In Cash	-1.666M	-896.0K	-2.308M
YoY Change	-9.6%		-27.15%
FREE CASH FLOW
Cash From Operating Activities	-$1.137M	-$421.0K	-$540.0K
Capital Expenditures	$476.0K	$475.0K	$2.000M
Free Cash Flow	-$1.613M	-$896.0K	-$2.540M
YoY Change	-14.88%		-20.48%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0000096793
CY2023	us-gaap	Change In Accounting Principle Accounting Standards Update Transition Option Elected Extensible List ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList	http://fasb.org/us-gaap/2022#AccountingStandardsUpdate201409Member
CY2022	ssy	Age Of Participants To Take Monthly Pension Benefits One AgeOfParticipantsToTakeMonthlyPensionBenefitsOne	P65Y
CY2023Q2	us-gaap	Change In Accounting Principle Accounting Standards Update Adopted ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted	true
CY2023Q2	us-gaap	Change In Accounting Principle Accounting Standards Update Immaterial Effect ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect	true
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Entity Registrant Name EntityRegistrantName	SUNLINK HEALTH SYSTEMS, INC.
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q2	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentGross
CY2022Q2	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentGross
CY2023Q2	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#LongTermDebtCurrent
CY2022Q2	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#LongTermDebtCurrent
CY2023Q2	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#LongTermDebtNoncurrent
CY2022Q2	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#LongTermDebtNoncurrent
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	1-12607
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	OH
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	31-0621189
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	900 Circle 75 Parkway
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 690
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Atlanta
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	GA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	30339
CY2023	dei	City Area Code CityAreaCode	770
CY2023	dei	Local Phone Number LocalPhoneNumber	933-7000
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	7031603
CY2022Q4	dei	Entity Public Float EntityPublicFloat	3133509
CY2023	dei	Auditor Name AuditorName	Cherry Bekaert, LLP
CY2023	dei	Auditor Location AuditorLocation	Atlanta, Georgia
CY2023	dei	Auditor Firm AuditorFirmId	677
CY2022Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	40000
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1388000
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1520000
CY2023Q2	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	179000
CY2022Q2	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	2600000
CY2023Q2	ssy	Unearned Cares Act Funds UnearnedCARESActFunds	20000
CY2022Q2	ssy	Unearned Cares Act Funds UnearnedCARESActFunds	519000
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4486000
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6794000
CY2023Q2	us-gaap	Receivables Net Current ReceivablesNetCurrent	4251000
CY2022Q2	us-gaap	Receivables Net Current ReceivablesNetCurrent	4624000
CY2023Q2	us-gaap	Inventory Net InventoryNet	1754000
CY2022Q2	us-gaap	Inventory Net InventoryNet	1748000
CY2023Q2	ssy	Employee Retention Credits Receivable Current EmployeeRetentionCreditsReceivableCurrent	0
CY2022Q2	ssy	Employee Retention Credits Receivable Current EmployeeRetentionCreditsReceivableCurrent	1761000
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1783000
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1888000
CY2023Q2	us-gaap	Assets Current AssetsCurrent	12274000
CY2022Q2	us-gaap	Assets Current AssetsCurrent	16815000
CY2023Q2	us-gaap	Land Land	582000
CY2022Q2	us-gaap	Land Land	582000
CY2023Q2	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	7279000
CY2022Q2	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	7381000
CY2023Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	16293000
CY2022Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	15957000
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	24154000
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	23920000
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	15873000
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	15703000
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8281000
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8217000
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1180000
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1201000
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1045000
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1187000
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	489000
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	523000
CY2023Q2	us-gaap	Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment	2714000
CY2022Q2	us-gaap	Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment	2911000
CY2023Q2	us-gaap	Assets Assets	23269000
CY2022Q2	us-gaap	Assets Assets	27943000
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1849000
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1347000
CY2023Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	14000
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	395000
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	352000
CY2023Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1024000
CY2022Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1313000
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	4869000
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	7691000
CY2023Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0
CY2022Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	14000
CY2023Q2	ssy	Professional Liability Risks Non Current ProfessionalLiabilityRisksNonCurrent	138000
CY2022Q2	ssy	Professional Liability Risks Non Current ProfessionalLiabilityRisksNonCurrent	86000
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	674000
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	857000
CY2023Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	69000
CY2022Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	69000
CY2023Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	102000
CY2022Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	106000
CY2023Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	983000
CY2022Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1132000
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2023Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2022Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	12000000
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	12000000
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7032000
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7032000
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6954000
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6954000
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	3516000
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	3478000
CY2023Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	10746000
CY2022Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	10736000
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	3005000
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	4800000
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	150000
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	106000
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	17417000
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	19120000
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	23269000
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	27943000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	47949000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	41344000
CY2023	us-gaap	Labor And Related Expense LaborAndRelatedExpense	19193000
CY2022	us-gaap	Labor And Related Expense LaborAndRelatedExpense	19006000
CY2023	us-gaap	Supplies Expense SuppliesExpense	1363000
CY2022	us-gaap	Supplies Expense SuppliesExpense	1276000
CY2023	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	4763000
CY2022	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	4345000
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	500000
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	552000
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1765000
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1543000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-2322000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-5340000
CY2023	ssy	Federal Stimulus Pandemic Relief Funds FederalStimulusPandemicReliefFunds	510000
CY2022	ssy	Federal Stimulus Pandemic Relief Funds FederalStimulusPandemicReliefFunds	720000
CY2023	ssy	Forgiveness Of Ppp Loans And Accrued Interest ForgivenessOfPPPLoansAndAccruedInterest	0
CY2022	ssy	Forgiveness Of Ppp Loans And Accrued Interest ForgivenessOfPPPLoansAndAccruedInterest	3010000
CY2023	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	120000
CY2022	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-15000
CY2023	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets	30000
CY2022	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets	10000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1662000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1615000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-7000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	107000
CY2023	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-1655000
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-1722000
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-140000
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-287000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1795000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2009000
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	44000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	268000
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1751000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1741000
CY2023	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.24
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.25
CY2023	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.24
CY2022	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.25
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.02
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.04
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.02
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.04
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.29
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.29
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7019000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6945000
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7019000
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6945000
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	20810000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2009000
CY2022	ssy	Other Comprehensive Income Loss Minimum Pension Liability Adjustment Net Of Tax OtherComprehensiveIncomeLossMinimumPensionLiabilityAdjustmentNetOfTax	268000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	51000
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	19120000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1795000
CY2023	ssy	Other Comprehensive Income Loss Minimum Pension Liability Adjustment Net Of Tax OtherComprehensiveIncomeLossMinimumPensionLiabilityAdjustmentNetOfTax	44000
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	48000
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	17417000
CY2023	us-gaap	Profit Loss ProfitLoss	-1795000
CY2022	us-gaap	Profit Loss ProfitLoss	-2009000
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1765000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1543000
CY2023	ssy	Forgiveness Of Paycheck Protection Plan Loans And Accrued Interest ForgivenessOfPaycheckProtectionPlanLoansAndAccruedInterest	0
CY2022	ssy	Forgiveness Of Paycheck Protection Plan Loans And Accrued Interest ForgivenessOfPaycheckProtectionPlanLoansAndAccruedInterest	3010000
CY2023	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	38000
CY2022	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-69000
CY2023	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	770000
CY2022	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	967000
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	30000
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	10000
CY2023	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	397000
CY2022	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	1402000
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6000
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-143000
CY2023	ssy	Increase Decrease In Employee Retention Credits Receivable IncreaseDecreaseInEmployeeRetentionCreditsReceivable	-1761000
CY2022	ssy	Increase Decrease In Employee Retention Credits Receivable IncreaseDecreaseInEmployeeRetentionCreditsReceivable	-1825000
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-281000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-565000
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	69000
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	599000
CY2023	ssy	Increase Decrease In Deferred Relief Funds IncreaseDecreaseInDeferredReliefFunds	-499000
CY2022	ssy	Increase Decrease In Deferred Relief Funds IncreaseDecreaseInDeferredReliefFunds	82000
CY2023	ssy	Increase Decrease In Accrued Sales Taxes IncreaseDecreaseInAccruedSalesTaxes	-2421000
CY2022	ssy	Increase Decrease In Accrued Sales Taxes IncreaseDecreaseInAccruedSalesTaxes	634000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-540000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4000
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	224000
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	11000
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2000000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3190000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1776000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3179000
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	48000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	51000
CY2023	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	40000
CY2022	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	36000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-2308000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-3168000
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6794000
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9962000
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4486000
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6794000
CY2023	ssy	Right Of Use Asset Obtained In Exchange For Lease Liability RightOfUseAssetObtainedInExchangeForLeaseLiability	222000
CY2022	ssy	Right Of Use Asset Obtained In Exchange For Lease Liability RightOfUseAssetObtainedInExchangeForLeaseLiability	370000
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	141000
CY2023	ssy	Interest Paid Received Net InterestPaidReceivedNet	-120000
CY2022	ssy	Interest Paid Received Net InterestPaidReceivedNet	5000
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">1. BUSINESS OPERATIONS</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">SunLink Health Systems, Inc., through subsidiaries (“SunLink”, “we”, “our”, “ours”, “us” or the “Company”), owns businesses which are providers of healthcare services in certain markets in the United States. SunLink’s business is composed of the ownership of </span><span style="font-size:10pt;font-family:'Times New Roman',serif;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> business segments:</span></p><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Healthcare Services</span></p><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">The Healthcare Services business is composed of:</span></p><div style="margin-left:9.065%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">•</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">A subsidiary which owns and operates Trace Regional Medical Center (“Trace”) which is comprised of a </span><span style="font-size:10pt;font-family:'Times New Roman',serif;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">49</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> licensed-bed acute care hospital, located in Houston, Mississippi. Our Medical Center also includes an </span><span style="font-size:10pt;font-family:'Times New Roman',serif;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">18</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">-bed geriatric psychiatry unit (“GPU”), and a </span><span style="font-size:10pt;font-family:'Times New Roman',serif;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">66</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">-bed extended care and rehabilitation center. This facility focuses primarily on senior healthcare services.</span></div></div><div style="margin-left:9.065%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">•</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;"></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">subsidiary, SunLink Health Systems Technology (“SHST Technology”), which provides information technology (“IT”) to outside customers and to SunLink subsidiaries. </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></div></div><div style="margin-left:9.065%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">•</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;"></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">subsidiary which owns approximately five (</span><span style="font-size:10pt;font-family:'Times New Roman',serif;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">) acres of unimproved land in Houston, Mississippi. </span></div></div><div style="margin-left:9.065%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">•</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">A subsidiary which owns approximately </span><span style="font-size:10pt;font-family:'Times New Roman',serif;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> acres of unimproved land in Ellijay, Georgia. </span></div></div><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Pharmacy</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">The Pharmacy business, which is composed of </span><span style="font-size:10pt;font-family:'Times New Roman',serif;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">four</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> operational areas:</span></p><div style="margin-left:9.065%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">•</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Retail pharmacy products and services, consisting of retail pharmacy sales conducted in rural markets at </span><span style="font-size:10pt;font-family:'Times New Roman',serif;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> locations in Louisiana. </span></div></div><div style="margin-left:9.065%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">•</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Institutional pharmacy services consisting of the provision of specialty and non-specialty pharmaceutical and biological products to institutional clients or to patients in institutional settings, such as extended care and rehabilitation centers, nursing homes, assisted living facilities, behavioral and specialty hospitals, hospice, and correctional facilities.</span></div></div><div style="margin-left:9.065%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">•</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Non-institutional Pharmacy services consisting of the provision of specialty and non-specialty pharmaceutical and biological products to clients or patients in non-institutional settings including private residential homes. </span></div></div><div style="margin-left:9.065%;text-indent:0;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">•</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Durable medical equipment products and services (“DME”), consisting primarily of the sale and rental of products for institutional clients or to patients in institutional settings and patient-administered home care.</span></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">SunLink subsidiaries have conducted the Healthcare Services business since 2001 and the Pharmacy operations since 2008. Our Pharmacy segment currently is operated through Carmichael’s Cashway Pharmacy, Inc. (“Carmichael”), a subsidiary of our SunLink ScriptsRx, LLC subsidiary.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">Throughout these notes to the consolidated financial statements, SunLink Health Systems, Inc., and its consolidated subsidiaries are referred to on a collective basis as “SunLink”, “we”, “our”, “ours”, “us” or the “Company.” This drafting style is not meant to indicate that the publicly traded Company or any particular subsidiary of the Company owns or operates any asset, business or property. The operations and businesses described in this filing are owned and operated by distinct and indirect subsidiaries of SunLink Health System, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">COVID-19 Pandemic and CARES Act Funding</span></p><p style="text-indent:4.173%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">COVID-19 was declared a global pandemic by the World Health Organization on March 11, 2020. We believe the effect of the COVID-19 pandemic and its aftermath and certain of the public and certain governmental responses to it have in varying degrees negatively affected each of our last thirteen quarter’s results.</span><span style="color:#212529;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:1pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> During the pandemic and its aftermath our Healthcare business experienced material reductions in demand and net revenues. Shortages of and increased costs of certain medical supplies and equipment related to the pandemic as well as increases in the levels of salaries, wages and benefits, have continued adversely to affect our Healthcare businesses. In addition, we experienced loss of some employees, including clinical staff, believed due to, among other things, federally mandated vaccination of healthcare workers against COVID-19.</span><span style="color:#212529;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:1pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> Our Pharmacy business also experienced reduced sales trends in certain areas, increased costs and reduced staff due to the COVID-19 pandemic and its aftermath as well as material reductions in demand and net revenues. Many of our primary physician referral sources operated at reduced capacity, and not all have resumed operating at full capacity. We believe the COVID-19 pandemic and its aftermath continues negatively to affect the cost of, and result in a lack of inventory for, certain DME products and Retail and Institutional Pharmacy drugs and products. Our Institutional Pharmacy services also experienced increased costs and operational inefficiencies due to measures taken by us and restrictions implemented by our institutional customers in response to the COVID-19 pandemic and its aftermath.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:1pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> Our Healthcare and Pharmacy segments have received approximately $</span><span style="font-size:10pt;font-family:'Times New Roman',serif;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">6,182</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> in general and targeted Provider Relief Funds ("PRF") during the period April 1, 2020 through June 30, 2023 under the CARES Act, which was enacted in March 2020 in response to the COVID-19 pandemic. The PRF distributions have been accounted for as government grants, and a total of $</span><span style="font-size:10pt;font-family:'Times New Roman',serif;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">6,162</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> have been recognized since April l, 2020 as other income under the gain contingency recognition method.</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:1pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> During the quarter ended June 30, 2020, our Healthcare and Pharmacy segments received $</span><span style="font-size:10pt;font-family:'Times New Roman',serif;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">3,234</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> in Paycheck Protection Plan (“PPP”) loans provided under the CARES Act. These loans were forgivable upon compliance with conditions specified under the PPP loan program. As of June 30, 2022, all our PPP loans have been forgiven.</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:1pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> The Taxpayer Certainty and Disaster Tax Relief Act of 2020, enacted December 27, 2020, made a number of changes to employer retention tax credits previously made available under the CARES Act, including modifying and extending the Employee Retention Credit ("ERC") for the six calendar months ending June 30, 2021. As a result of such legislation, the Company qualified for ERC for the first and second calendar quarters of 2021 due to the decrease in its gross receipts and applied for ERC of $</span><span style="font-size:10pt;font-family:'Times New Roman',serif;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">3,586</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> through amended quarterly payroll tax filings for the applicable quarters. As of June 30, 2023, the Company has received all of the ERC which we applied for. We continue to monitor compliance with the terms and conditions of the ERC and PPP programs and developing interpretations and enforcement of the ERC and PPP program rules and the regulations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:1pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> PRF distributions, PPP loan forgiveness and other grants received during the pandemic are subject to Federal audits and Single Audits and not subject to repayment provided we are able to attest to and comply with the terms and conditions of the funding, including demonstrating that the funds received have been used for designated, allowable healthcare-related expenses and capital expenditures attributable to COVID-19 and for "Lost Revenues" as defined by the department of “HHS”. We continue to monitor compliance with the terms and conditions of such funds received, as well as the impact of the pandemic on our revenues and expenses. If we are unable to attest to or comply with current or future terms and conditions, and there is no assurance we will continue to be able to do so, our ability to retain some or all of such funds received may be impacted, and we may have to return the unutilized portion of those funds, if any, in the future. The Company filed its Schedule of Grant Income of HHS awards and audit report for the year ended June 30, 2021 with the Health Resources and Services Administration (“HRSA”) agency of HHS on September 30, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p>
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2
CY2023	ssy	Employee Retention Credit Qualified Wages Limited Per Employee Per Quarter EmployeeRetentionCreditQualifiedWagesLimitedPerEmployeePerQuarter	3586000
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;font-style:italic;min-width:fit-content;">Management Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> —The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Some of the more significant estimates made by management involve reserves for adjustments to net patient service revenues, evaluation of the recoverability of assets, including accounts receivable and intangible assets, and the assessment of litigation and contingencies, including income taxes and related tax asset valuation allowances, all as discussed in more detail in the remainder of these notes to the consolidated financial statements. Actual results could differ materially from these estimates.</span></p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Times New Roman',serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> —SunLink’s Healthcare Services segment subsidiaries grant unsecured credit to their patients, most of who reside in the service area of the subsidiaries’ facilities and are insured under third-party agreements. Medicare and Medicaid patient accounts represent SunLink’s only significant concentrations of credit risk. For SunLink’s Healthcare Services segment, Medicare net revenues were approximately </span><span style="font-size:10pt;font-family:'Times New Roman',serif;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">39</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:'Times New Roman',serif;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">57</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">% of net revenues for the years ended June 30, 2023 and 2022, respectively. For SunLink’s Healthcare Services segment, Medicaid was approximately </span><span style="font-size:10pt;font-family:'Times New Roman',serif;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">34</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:'Times New Roman',serif;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">32</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">% net revenues for the years ended June 30, 2023 and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">SunLink’s Pharmacy segment subsidiary grants unsecured credit to individual customers and institutional customers. Individual customers primarily are insured under third-party agreements, including Medicare and Medicaid, while the institutional customers are granted credit according to their determined credit risk. Medicare receivables were approximately </span><span style="font-size:10pt;font-family:'Times New Roman',serif;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">32</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:'Times New Roman',serif;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">30</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;">% of the Pharmacy segment’s receivables at June 30, 2023 and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Times New Roman',serif;min-width:fit-content;"> </span></p>
CY2023Q2	us-gaap	Cash Cash	4486000
CY2023	ssy	Overnight Repurchase Agreements Collateralized By Government Backed Securities OvernightRepurchaseAgreementsCollateralizedByGovernmentBackedSecurities	1.02
CY2023Q2	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	1191000
CY2022Q2	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	1133000
CY2023Q2	us-gaap	Workers Compensation Liability Current And Noncurrent WorkersCompensationLiabilityCurrentAndNoncurrent	150
CY2022Q2	us-gaap	Workers Compensation Liability Current And Noncurrent WorkersCompensationLiabilityCurrentAndNoncurrent	150
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	370000
CY2023	us-gaap	Depreciation Depreciation	1744000
CY2022	us-gaap	Depreciation Depreciation	1517000
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y10M9D
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	0
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	0
CY2023	ssy	Disposal Group Including Discontinued Operation Revenue Net Of Expenses DisposalGroupIncludingDiscontinuedOperationRevenueNetOfExpenses	21000
CY2022	ssy	Disposal Group Including Discontinued Operation Revenue Net Of Expenses DisposalGroupIncludingDiscontinuedOperationRevenueNetOfExpenses	24000
CY2023	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-140000
CY2022	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-287000
CY2023	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	0
CY2022	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	0
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-140000
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-287000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	47949000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	41344000
CY2023	ssy	Health Care Organization Significant Change In Estimates HealthCareOrganizationSignificantChangeInEstimates	151000
CY2022	ssy	Health Care Organization Significant Change In Estimates HealthCareOrganizationSignificantChangeInEstimates	33000
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y6M3D
CY2023Q2	us-gaap	Inventory Net InventoryNet	1754000
CY2022Q2	us-gaap	Inventory Net InventoryNet	1748000
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	398000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	468000
CY2023	ssy	Short Term Lease Cost Income ShortTermLeaseCostIncome	99000
CY2022	ssy	Short Term Lease Cost Income ShortTermLeaseCostIncome	82000
CY2023	ssy	Operating Variable Lease Cost OperatingVariableLeaseCost	3000
CY2022	ssy	Operating Variable Lease Cost OperatingVariableLeaseCost	2000
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	500000
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	552000
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	39000
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	36000
CY2023	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	2000
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	5000
CY2023	ssy	Finance Lease Cost FinanceLeaseCost	41000
CY2022	ssy	Finance Lease Cost FinanceLeaseCost	41000
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1045000
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1187000
CY2023Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	203000
CY2022Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	203000
CY2023Q2	us-gaap	Property Plant And Equipment Owned Accumulated Depreciation PropertyPlantAndEquipmentOwnedAccumulatedDepreciation	130000
CY2022Q2	us-gaap	Property Plant And Equipment Owned Accumulated Depreciation PropertyPlantAndEquipmentOwnedAccumulatedDepreciation	101000
CY2023Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	14000
CY2022Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	40000
CY2023Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	0
CY2022Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	14000
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	405000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	471000
CY2023	ssy	Operating Cash Flows From Finance Lease OperatingCashFlowsFromFinanceLease	2000
CY2022	ssy	Operating Cash Flows From Finance Lease OperatingCashFlowsFromFinanceLease	5000
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	39000
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	36000
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	222000
CY2023Q2	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P0Y4M28D
CY2022Q2	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y4M28D
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0145
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0103
CY2023Q2	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0654
CY2022Q2	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0654
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	404000
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	15000
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	383000
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	0
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	226000
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	0
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	60000
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	0
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	9000
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	0
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	0
CY2023Q2	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	0
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1082000
CY2023Q2	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	15000
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	13000
CY2023Q2	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	1000
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	1069000
CY2023Q2	us-gaap	Finance Lease Liability FinanceLeaseLiability	14000
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	395000
CY2023Q2	ssy	Finance Leases Liability Current FinanceLeasesLiabilityCurrent	0
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	674000
CY2023Q2	ssy	Finance Leases Liability Noncurrent FinanceLeasesLiabilityNoncurrent	14000
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	21000
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	26000
CY2023Q2	ssy	Finance Lease Obligations FinanceLeaseObligations	14000
CY2022Q2	ssy	Finance Lease Obligations FinanceLeaseObligations	54000
CY2023Q2	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	14000
CY2022Q2	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	40000
CY2023Q2	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	0
CY2022Q2	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	14000
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	14000
CY2023Q2	ssy	Long Term Debt Contractual Commitments For Interest In Next Twelve Months LongTermDebtContractualCommitmentsForInterestInNextTwelveMonths	1000
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	0
CY2023Q2	ssy	Long Term Debt Contractual Commitments For Interest In Year Two LongTermDebtContractualCommitmentsForInterestInYearTwo	0
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	0
CY2023Q2	ssy	Long Term Debt Contractual Commitments For Interest In Year Three LongTermDebtContractualCommitmentsForInterestInYearThree	0
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	0
CY2023Q2	ssy	Long Term Debt Contractual Commitments For Interest In Year Four LongTermDebtContractualCommitmentsForInterestInYearFour	0
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	0
CY2023Q2	ssy	Long Term Debt Contractual Commitments For Interest In Year Five LongTermDebtContractualCommitmentsForInterestInYearFive	0
CY2023Q2	ssy	Long Term Debt Maturities Repayments Of Principal In Year Six And After Year Six LongTermDebtMaturitiesRepaymentsOfPrincipalInYearSixAndAfterYearSix	0
CY2023Q2	ssy	Long Term Debt Contractual Commitments For Interest In Year Six And After Year Six LongTermDebtContractualCommitmentsForInterestInYearSixAndAfterYearSix	0
CY2023Q2	us-gaap	Long Term Debt LongTermDebt	14000
CY2023Q2	ssy	Long Term Debt Contractual Commitments LongTermDebtContractualCommitments	1000
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	410000
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.34
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	30000
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.67
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	380000
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.31
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	195000
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.22
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	185000
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.41
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	380000
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.31
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	185000
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.41
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0
CY2023Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	0
CY2022Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	0
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	185000
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P2Y5M15D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	185000
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	195000
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	30000
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	3000
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	3000
CY2021Q2	us-gaap	Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax	-162000
CY2021Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-162000
CY2022	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	268000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	268000
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax	106000
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	106000
CY2023	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	44000
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	44000
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax	150000
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	150000
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	31000
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	38000
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-38000
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	69000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-7000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	107000
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	8003000
CY2022Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	7275000
CY2023Q2	ssy	Deferred Tax Assets Depreciation Expense DeferredTaxAssetsDepreciationExpense	-128000
CY2022Q2	ssy	Deferred Tax Assets Depreciation Expense DeferredTaxAssetsDepreciationExpense	-122000
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	295000
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	255000
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	218000
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	237000
CY2023Q2	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	-251000
CY2022Q2	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	-35000
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Pensions DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPensions	0
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Pensions DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPensions	32000
CY2023Q2	ssy	Deferred Tax Asset Provider Relief Funds DeferredTaxAssetProviderReliefFunds	0
CY2022Q2	ssy	Deferred Tax Asset Provider Relief Funds DeferredTaxAssetProviderReliefFunds	126000
CY2023Q2	ssy	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	233000
CY2022Q2	ssy	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	292000
CY2023Q2	ssy	Deferred Tax Assets Right Of Use Liabilities DeferredTaxAssetsRightOfUseLiabilities	234000
CY2022Q2	ssy	Deferred Tax Assets Right Of Use Liabilities DeferredTaxAssetsRightOfUseLiabilities	291000
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	79000
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	83000
CY2023Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	8217000
CY2022Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	7850000
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	8286000
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	7919000
CY2023Q2	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	69000
CY2022Q2	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	69000
CY2023	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate	0.0450
CY2022	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate	0.0280
CY2023	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Expected Long Term Return On Assets DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets	0.0400
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-323000
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-339000
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	314000
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	968000
CY2023	us-gaap	Income Tax Reconciliation Tax Settlements State And Local IncomeTaxReconciliationTaxSettlementsStateAndLocal	-18000
CY2022	us-gaap	Income Tax Reconciliation Tax Settlements State And Local IncomeTaxReconciliationTaxSettlementsStateAndLocal	48000
CY2023	ssy	Income Tax Reconciliation Permanent Differences Relating To Paycheck Protection Plan Loan Forgiveness IncomeTaxReconciliationPermanentDifferencesRelatingToPaycheckProtectionPlanLoanForgiveness	0
CY2022	ssy	Income Tax Reconciliation Permanent Differences Relating To Paycheck Protection Plan Loan Forgiveness IncomeTaxReconciliationPermanentDifferencesRelatingToPaycheckProtectionPlanLoanForgiveness	-632000
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	20000
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	62000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-7000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	107000
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	8286000
CY2023Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2022Q2	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	69000
CY2023Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	24802000
CY2023Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	24802000
CY2023	ssy	Net Operating Loss Carry Forwards Expire Period NetOperatingLossCarryForwardsExpirePeriod	2024 through fiscal 2038
CY2023	ssy	Defined Contribution Plan Employer Matching Contribution DefinedContributionPlanEmployerMatchingContribution	0
CY2022	ssy	Defined Contribution Plan Employer Matching Contribution DefinedContributionPlanEmployerMatchingContribution	0
CY2023	us-gaap	Deferred Compensation Arrangement With Individual Compensation Expense DeferredCompensationArrangementWithIndividualCompensationExpense	0
CY2022	us-gaap	Deferred Compensation Arrangement With Individual Compensation Expense DeferredCompensationArrangementWithIndividualCompensationExpense	0
CY2023Q2	ssy	Plans Assets Invested In Cash And Short Term Investments PlansAssetsInvestedInCashAndShortTermInvestments	0.27
CY2023Q2	ssy	Plans Assets Invested In Equity Investments PlansAssetsInvestedInEquityInvestments	0.56
CY2023Q2	ssy	Plans Assets Invested In Fixed Income Investments PlansAssetsInvestedInFixedIncomeInvestments	0.17
CY2023	ssy	Expected Return On Investment ExpectedReturnOnInvestment	0.04
CY2023Q2	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Next Twelve Months DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths	30000
CY2023Q2	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Year Two DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo	125000
CY2023Q2	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Year Three DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree	37000
CY2023Q2	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Year Four DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour	45000
CY2023Q2	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Year Five DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive	45000
CY2023Q2	ssy	Plan Expected To Pay In Pension Benefits Through Three Years PlanExpectedToPayInPensionBenefitsThroughThreeYears	268000
CY2023	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	88000
CY2022	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	100000
CY2023Q2	us-gaap	Defined Benefit Plan Expected Future Employer Contributions Next Fiscal Year DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear	100000
CY2022	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Expected Long Term Return On Assets DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets	0.0400
CY2023	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Rate Of Compensation Increase DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease	0.0000
CY2022	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Rate Of Compensation Increase DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease	0.0000
CY2022Q2	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	1172000
CY2021Q2	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	1535000
CY2023	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	52000
CY2022	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	42000
CY2023	us-gaap	Defined Benefit Plan Actuarial Gain Loss DefinedBenefitPlanActuarialGainLoss	67000
CY2022	us-gaap	Defined Benefit Plan Actuarial Gain Loss DefinedBenefitPlanActuarialGainLoss	378000
CY2023	us-gaap	Defined Benefit Plan Benefit Obligation Benefits Paid DefinedBenefitPlanBenefitObligationBenefitsPaid	332000
CY2022	us-gaap	Defined Benefit Plan Benefit Obligation Benefits Paid DefinedBenefitPlanBenefitObligationBenefitsPaid	27000
CY2023	us-gaap	Defined Benefit Plan Benefit Obligation Payment For Settlement DefinedBenefitPlanBenefitObligationPaymentForSettlement	23000
CY2022	us-gaap	Defined Benefit Plan Benefit Obligation Payment For Settlement DefinedBenefitPlanBenefitObligationPaymentForSettlement	0
CY2023Q2	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	848000
CY2022Q2	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	1172000
CY2022Q2	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	1041000
CY2021Q2	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	1080000
CY2023	us-gaap	Defined Benefit Plan Actual Return On Plan Assets DefinedBenefitPlanActualReturnOnPlanAssets	51000
CY2022	us-gaap	Defined Benefit Plan Actual Return On Plan Assets DefinedBenefitPlanActualReturnOnPlanAssets	-112000
CY2023	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	88000
CY2022	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	100000
CY2023	us-gaap	Defined Benefit Plan Plan Assets Benefits Paid DefinedBenefitPlanPlanAssetsBenefitsPaid	332000
CY2022	us-gaap	Defined Benefit Plan Plan Assets Benefits Paid DefinedBenefitPlanPlanAssetsBenefitsPaid	27000
CY2023Q2	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	848000
CY2022Q2	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	1041000
CY2023Q2	us-gaap	Defined Benefit Plan Funded Status Of Plan DefinedBenefitPlanFundedStatusOfPlan	0
CY2022Q2	us-gaap	Defined Benefit Plan Funded Status Of Plan DefinedBenefitPlanFundedStatusOfPlan	-131000
CY2023	ssy	Unrecognized Actuarial Loss UnrecognizedActuarialLoss	-20000
CY2022	ssy	Unrecognized Actuarial Loss UnrecognizedActuarialLoss	24000
CY2023Q2	ssy	Accrued Benefit Cost AccruedBenefitCost	-20000
CY2022Q2	ssy	Accrued Benefit Cost AccruedBenefitCost	-107000
CY2023Q2	ssy	Defined Benefit Plan Amounts Recognized In Accrued Benefit Cost DefinedBenefitPlanAmountsRecognizedInAccruedBenefitCost	-20000
CY2022Q2	ssy	Defined Benefit Plan Amounts Recognized In Accrued Benefit Cost DefinedBenefitPlanAmountsRecognizedInAccruedBenefitCost	-107000
CY2023Q2	ssy	Defined Benefit Plans Accumulated Other Comprehensive Income Minimum Pension Liability Before Tax DefinedBenefitPlansAccumulatedOtherComprehensiveIncomeMinimumPensionLiabilityBeforeTax	-20000
CY2022Q2	ssy	Defined Benefit Plans Accumulated Other Comprehensive Income Minimum Pension Liability Before Tax DefinedBenefitPlansAccumulatedOtherComprehensiveIncomeMinimumPensionLiabilityBeforeTax	24000
CY2023Q2	us-gaap	Defined Benefit Plan Amounts Recognized In Balance Sheet DefinedBenefitPlanAmountsRecognizedInBalanceSheet	0
CY2022Q2	us-gaap	Defined Benefit Plan Amounts Recognized In Balance Sheet DefinedBenefitPlanAmountsRecognizedInBalanceSheet	-131000
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-287000
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7019000
CY2023	ssy	Number Of Taxing Authorities NumberOfTaxingAuthorities	2
CY2020Q2	us-gaap	Income Tax Examination Liability Refund Adjustment From Settlement With Taxing Authority IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority	359000
CY2023Q2	us-gaap	Income Tax Examination Liability Refund Adjustment From Settlement With Taxing Authority IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority	1500000
CY2023Q2	us-gaap	Sales And Excise Tax Payable Current And Noncurrent SalesAndExciseTaxPayableCurrentAndNoncurrent	2615000
CY2023Q2	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	36000
CY2022Q2	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	15000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	47949000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-2322000
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1765000
CY2023Q2	us-gaap	Assets Assets	23269000
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2000000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	41344000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-5340000
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1543000
CY2022Q2	us-gaap	Assets Assets	27943000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3190000
CY2023	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-1655000
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-1722000
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7019000
CY2023	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.24
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6945000
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.25
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7019000
CY2023	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.24
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6945000
CY2022	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.25
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-140000
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.02
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6945000
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.04
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7019000
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.02
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6945000
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.04
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1795000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2009000
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7019000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6945000
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.29
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7019000
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6945000
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.29
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7019000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6945000
CY2023	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0
CY2022	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7019000
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6945000
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3000
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	92000

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0000950170-23-050285-index-headers.html	Edgar Link	pending
0000950170-23-050285-index.html	Edgar Link	pending
0000950170-23-050285.txt	Edgar Link	pending
0000950170-23-050285-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ssy-20230630.htm	Edgar Link	pending
ssy-20230630.xsd	Edgar Link	pending
ssy-ex21_1.htm	Edgar Link	pending
ssy-ex23_1.htm	Edgar Link	pending
ssy-ex31_1.htm	Edgar Link	pending
ssy-ex31_2.htm	Edgar Link	pending
ssy-ex32_1.htm	Edgar Link	pending
ssy-ex32_2.htm	Edgar Link	pending
ssy-20230630_def.xml	Edgar Link	unprocessable
ssy-20230630_cal.xml	Edgar Link	unprocessable
ssy-20230630_lab.xml	Edgar Link	unprocessable
ssy-20230630_pre.xml	Edgar Link	unprocessable
ssy-20230630_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SSY
SUNLINK HEALTH SYSTEMS INC Stock $ssy

2023 Q3 Form 10-K Financial Statement

#000095017023050285 Filed on September 28, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SSY SUNLINK HEALTH SYSTEMS INC Stock $ssy

2023 Q3 Form 10-K Financial Statement

#000095017023050285 Filed on September 28, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SSY
SUNLINK HEALTH SYSTEMS INC Stock $ssy